142
Views
0
CrossRef citations to date
0
Altmetric
Commentaries

Venetoclax and hypomethylating agent therapy for accelerated and blast phase BCR::ABL negative myeloproliferative and extramedullary disease

&
Pages 757-760 | Received 06 Mar 2023, Accepted 06 Mar 2023, Published online: 10 Apr 2023
 

Acknowledgements

We thank Robert Hasserjian for input into the Figure.

Additional information

Funding

The author(s) reported there is no funding associated with the work featured in this article.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.